Replimune
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer.
CEOSushil Patel
CEOSushil Patel
Employees479
Employees479
HeadquartersWoburn, Massachusetts
HeadquartersWoburn, Massachusetts
Founded2015
Founded2015
Employees479
Employees479
REPL Key Statistics
Market cap783.65M
Market cap783.65M
Price-Earnings ratio-2.69
Price-Earnings ratio-2.69
Dividend yield—
Dividend yield—
Average volume1.44M
Average volume1.44M
High today$10.14
High today$10.14
Low today$9.68
Low today$9.68
Open price$9.73
Open price$9.73
Volume820.20K
Volume820.20K
52 Week high$14.80
52 Week high$14.80
52 Week low$2.68
52 Week low$2.68
Stock Snapshot
As of today, Replimune(REPL) shares are valued at $9.99. The company's market cap stands at 783.65M, with a P/E ratio of -2.69.
During the trading session on 2025-12-19, Replimune(REPL) shares reached a daily high of $10.14 and a low of $9.68. At a current price of $9.99, the stock is +3.2% higher than the low and still -1.5% under the high.
Trading volume for Replimune(REPL) stock has reached 820.2K, versus its average volume of 1.44M.
The stock's 52-week range extends from a low of $2.68 to a high of $14.80.
The stock's 52-week range extends from a low of $2.68 to a high of $14.80.
REPL News
Simply Wall St 2d
Insiders At Replimune Group Sold US$766k In Stock, Alluding To Potential WeaknessReplimune Group, Inc. ( ) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. Knowing whether insiders are b...
Analyst ratings
75%
of 8 ratingsBuy
75%
Hold
25%
Sell
0%
People also own
Based on the portfolios of people who own REPL. This list is generated using Robinhood data, and it’s not a recommendation.